Pharmas go on $11B buying binge

Pharmas have gone on a shopping spree, with four deals worth a total of up to US$7.6 billion (AU$10.98 billion) announced in the past two weeks. Roche has obtained an obesity candidate, Gilead is investing in immunotherapies, Viatris is pumping money into pain drugs, and Galderma is doubling down in dermatology.